Kiniksa Non Operating Income Net Other from 2010 to 2026
| KNSA Stock | USD 45.37 0.66 1.48% |
Non Operating Income Net Other | First Reported 2010-12-31 | Previous Quarter 1.1 M | Current Value 2.1 M | Quarterly Volatility 1.9 M |
Check Kiniksa Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kiniksa Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 6.7 M, Net Interest Income of 1.6 M or Interest Income of 1.6 M, as well as many indicators such as Price To Sales Ratio of 3.65, Dividend Yield of 0.0 or PTB Ratio of 3.05. Kiniksa financial statements analysis is a perfect complement when working with Kiniksa Pharmaceuticals Valuation or Volatility modules.
Kiniksa | Non Operating Income Net Other | Build AI portfolio with Kiniksa Stock |
Analyzing Kiniksa Pharmaceuticals's Non Operating Income Net Other over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Non Operating Income Net Other has evolved provides context for assessing Kiniksa Pharmaceuticals's current valuation and future prospects.
Latest Kiniksa Pharmaceuticals' Non Operating Income Net Other Growth Pattern
Below is the plot of the Non Operating Income Net Other of Kiniksa Pharmaceuticals over the last few years. It is Kiniksa Pharmaceuticals' Non Operating Income Net Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kiniksa Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Non Operating Income Net Other | 10 Years Trend |
|
Non Operating Income Net Other |
| Timeline |
Kiniksa Non Operating Income Net Other Regression Statistics
| Arithmetic Mean | 3,338,707 | |
| Geometric Mean | 2,431,600 | |
| Coefficient Of Variation | 57.65 | |
| Mean Deviation | 1,780,345 | |
| Median | 4,719,000 | |
| Standard Deviation | 1,924,927 | |
| Sample Variance | 3.7T | |
| Range | 6M | |
| R-Value | (0.76) | |
| Mean Square Error | 1.7T | |
| R-Squared | 0.57 | |
| Significance | 0.0004 | |
| Slope | (288,295) | |
| Total Sum of Squares | 59.3T |
Kiniksa Non Operating Income Net Other History
About Kiniksa Pharmaceuticals Financial Statements
Kiniksa Pharmaceuticals stakeholders use historical fundamental indicators, such as Kiniksa Pharmaceuticals' Non Operating Income Net Other, to determine how well the company is positioned to perform in the future. Although Kiniksa Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kiniksa Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Kiniksa Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kiniksa Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Operating Income Net Other | 1.1 M | 2.1 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kiniksa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiniksa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiniksa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiniksa Pharmaceuticals Stock:Check out the analysis of Kiniksa Pharmaceuticals Correlation against competitors. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. Expected growth trajectory for Kiniksa significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Kiniksa Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 5.5 | Earnings Share 0.45 | Revenue Per Share | Quarterly Revenue Growth 0.612 | Return On Assets |
Investors evaluate Kiniksa Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Kiniksa Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Kiniksa Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Kiniksa Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kiniksa Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Kiniksa Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.